ХОВОРОВА Анастасия (US),САЛОМОН Уильям (US),КАМЕНС Джоан (US),САМАРСКИЙ Дмитрий (US),ВУЛЬФ Тод М. (US),КАРДИА Джеймс (US)
申请号：
RU2012144738/04
公开号：
RU2012144738A
申请日:
2011.03.24
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. sd-rxPHK, wherein at least 40% modified nucleotides and wherein at least two Us and / or Cs include hydrophobic modification selected from the group consisting of methyl, octyl, thiophene, 1-octyne -ilnoy, ethynyl, piridilamidnoy, isobutyl and phenyl modifikatsii.2. sd-rxPHK according to claim 1, characterized in that at least 60% modifitsirovany.3 nucleotides. sd-rxPHK according to claim 1, characterized in that the modification comprises at least one or 2F 2O methyl modifikatsiyu.4. sd-rxPHK according to claim 1, characterized in that a plurality of Us and / or Cs hydrophobic modification include optionally selected from the group consisting of methyl, octyl, thiophene, octyn-1-yl, ethynyl, piridilamidnoy, isobutyl and phenyl modifications. 5. sd-rxPHK according to any one of claims 1-4, characterized in that the sd-rxPHK attached to linkeru.6. sd-rxPHK according to claim 5, characterized in that the linker is protoniruemym.7. sd-rxPHK according to claim 6, characterized in that the sd-rxPHK attached to linkerov.8 set. sd-rxPHK according to any one of claims 1-4, characterized in that the sd-rxPHK linked at the 3 end of a lipophilic gruppoy.9. sd-rxPHK according to claim 8, characterized in that the sd-rxPHK associated with holesterinom.10. sd-rxPHK according to claim 8, characterized in that the sd-rxPHK attached to vitamin A or vitamin E.11. sd-rxPHK according to any one of claims 1-4, characterized in that the driving string comprises a single-stranded region, comprising at least 5 modifikatsiy.12 phosphorothioate. sd-rxPHK according to claim 11, characterized in that the sd-rxPHK comprises at least two single chain oblasti.13. sd-rxPHK according to any one of claims 1-4, characterized in that the sd-rxPHK formulated into a composition for intravenous vvedeniya.14. sd-rxPHK according to any one of claims 1-4, characterized in that the sd-rxPHK formulated into a composition for subcutaneous administration1. sd-rxPHK, в которой, по меньшей мере, 40% нуклеотидо
